Background Pancreatic cancer is considered as a chemoresistant neoplasm with extremely
dismal prognosis. Gemcitabine is recommended as the standard agent for locally advanced …

Background This study aims to comprehensively summarize the currently available
evidences on the efficacy and safety of gemcitabine plus erlotinib for treating advanced …

Context The combination of gemcitabine and erlotinib is a standard first-line treatment for
unresectable, locally advanced or metastatic pancreatic cancer. We reviewed our single …

Purpose Patients with advanced pancreatic cancer have a poor prognosis and there have
been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic …

Background: Prognosis of advanced pancreatic cancer is dismal and the novel targeted
therapies, albeit successfully used to treat many advanced tumors, have shown modest …

Purpose Erlotinib has been the only targeted agent to show significantly improved outcomes
in pancreatic adenocarcinoma when combined with gemcitabine. We aimed to evaluate …

Background A randomized clinical trial has found that the addition of erlotinib to gemcitabine
(GEM-E) for pancreatic cancer led to a modest increase in survival. The aim of this national …

Background Gemcitabine has been recognized as a standard chemotherapy in advanced
pancreas cancer (APC). We conducted a phase II study of a triple combination regimen …

AIM: To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed
dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer. METHODS: We …

Little progress has been made on the treatment of advanced pancreatic cancer.
Gemcitabine has been an acceptable standard for more than a decade. The benefit of single …